Expertise in
12
conditions

Dr. Jan S. Moreb

Novant Health Thomasville Medical Center LLC
Thomasville, NC
Expertise in
12
conditions
Specialties:Hematology | Transplant Surgery | Oncology
Age:73
Accepting New Patients
Offers Telehealth
43 Years of Experience
Expertise in
12
conditions
OverviewInsuranceLocationsClinical Research

Overview

Jan Moreb is a Hematologist and a Transplant Surgeon in Thomasville, North Carolina. Dr. Moreb has been practicing medicine for over 43 years is highly rated in 12 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Moreb is currently accepting new patients.

His clinical research consists of co-authoring 64 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Transplant Surgery
Oncology
Licenses
Internal Medicine in NC
Hospital Affiliations
Novant Health Thomasville Medical Center
Novant Health Forsyth Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Cigna
  •  Blue Cross Blue Shield
  •  Humana

Locations

NOVANT HEALTH THOMASVILLE MEDICAL CENTER LLC
1213 Lexington Ave, Suite B, Thomasville, NC 27360
336-481-1950

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
A Randomized, Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment With Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients Up to 65 Years of Age
Enrollment Status: Active_not_recruiting
Publish Date: January 06, 2025
Intervention Type: Drug, Procedure
Study Drugs: Lenalidomide, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug
Study Drugs: Panobinostat Capsules, Bortezomib Injection, Dexamethasone Tablets
Study Phase: Phase 2
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination With Dexamethasone in Patients With Relapsed Refractory Multiple Myeloma Who Are Refractory to Pomalidomide and/or an Anti-CD38 Monoclonal Antibody
Enrollment Status: Completed
Publish Date: November 22, 2022
Intervention Type: Drug
Study Drugs: Melphalan Flufenamide (Melflufen), Dexamethasone
Study Phase: Phase 2
Randomized Controlled, Open-Label Study on the Use of Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant Patients
Randomized Controlled, Open-Label Study on the Use of Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant Patients
Enrollment Status: Terminated
Publish Date: December 05, 2018
Intervention Type: Other
Study Phase: Not Applicable
View 3 Less Clinical Trials

65 Total Publications

The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
The effect of mobilizing large numbers of CD34 + cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation.
Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
Published: May 01, 2023
Similar Doctors
Expertise in
18
conditions
Dr. Ruben A. Mesa
Hematology | Hematology Oncology | Oncology
Expertise in
18
conditions
Dr. Ruben A. Mesa
Hematology | Hematology Oncology | Oncology

The Charlotte-Mecklenburg Hospital Authority

1021 Morehead Medical Dr, Suite A, 
Charlotte, NC 
 (62.1 mi)
980-442-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Ruben Mesa is a Hematologist and a Hematologist Oncology provider in Charlotte, North Carolina. Dr. Mesa is highly rated in 18 conditions, according to our data. His top areas of expertise are Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Bone Marrow Transplant, and Splenectomy. Dr. Mesa is currently accepting new patients.

Expertise in
15
conditions
Dr. Sascha A. Tuchman
Hematology | Oncology | Transplant Surgery
Expertise in
15
conditions
Dr. Sascha A. Tuchman
Hematology | Oncology | Transplant Surgery

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (59.3 mi)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sascha Tuchman is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Tuchman is highly rated in 15 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Cardiac Amyloidosis, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Tuchman is currently accepting new patients.

Expertise in
18
conditions
Dr. Deborah M. Stephens
Hematology | Oncology | Hematology Oncology
Expertise in
18
conditions
Dr. Deborah M. Stephens
Hematology | Oncology | Hematology Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (59.3 mi)
984-974-1000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Deborah Stephens is a Hematologist and an Oncologist in Chapel Hill, North Carolina. Dr. Stephens is highly rated in 18 conditions, according to our data. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Stephens is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile